Corcept Therapeutics: Soaring Revenue & Promising Oncology Data

Corcept Therapeutics 2025 financials show strength, with revenue up and net income at $99.7 million. Korlym, their Cushings syndrome drug, is seeing increased demand, and a new specialty pharmacy is handling the surge. Trials like CATALYST highlight the conditions prevalence in diabetes and hypertension patients. Korlyms benefits include improved HbA1c, weight loss, and reduced waist size. The companys Cushings business could reach $2 billion annually by 2030. Relacorilant for Cushings faces FDA hurdles, but oncology trials are promising, with ROSELLA cutting death risk by 35% in platinum-resistant ovarian cancer. Corcepts pipeline includes more relacorilant trials and ALS data showing an 84% lower death risk. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3685c8f24b3d729d